Oruka Therapeutics, Inc. ORKA
99.55 USD +4.12 (+4.32%)
At closeNov 3, 2026, 4:00 PM EST
99.55 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
95.29 Day range 101.41
25.23 52-week range 115.52
- YTD
- +228.44%
- 1 year
- +280.11%
- Market cap
- 6.59B
- EPS (ttm)
- -2.04
- Shares out
- 66.21M
- Forward P/E
- -34.78
- YTD return
- +228.44%
- 1-year return
- +280.11%
- Volume
- 822.16K
- Avg volume
- 890.09K
- Open
- 97.48
- Previous close
- 95.43
- Day's range
- 95.29 – 101.41
- 52-week range
- 25.23 – 115.52
- Beta
- -0.17
- Analysts
- Strong Buy
- Price target
- 156.17 (+56.9%)
- Earnings date
- Nov 11, 2026
2Y +72.64 (+269.54%)
Key statistics
- Enterprise value
- 5.45B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -65.03M
- Total cash
- 873.56M
- Total debt
- 2.55M
- Return on equity
- -18.23%
- Short % of float
- 13.44%
- 50-day average
- 88.22
- 200-day average
- 69.55
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 156.17 +56.9% upside
Now 99.55
- Target (low)
- 117.00
- Target (mean)
- 156.17
- Target (high)
- 200.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy2
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.61832.
Financials — quick view
ORKA Revenue — quarterly 0
ORKA Net income — quarterly -41.21M
ORKA EPS — quarterly -0.55
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.59959 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.51249 | -0.55 | -0.04 | -7.32% |
| May 13, 2026 | Mar 31, 2026 | -0.54692 | -0.48 | +0.07 | +12.24% |
| Mar 12, 2026 | Dec 31, 2025 | -0.61 | -0.45 | +0.16 | +26.23% |
| Nov 12, 2025 | Sep 30, 2025 | -0.56 | -0.55 | +0.01 | +1.79% |
| Aug 11, 2025 | Jun 30, 2025 | -0.48 | -0.46 | +0.02 | +4.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Guggenheim | reit | Buy | Buy |
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Sep 24, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- orukatx.com
News
Oruka Therapeutics to Participate in Multiple Upcoming Conferences 
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target 
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target 
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target 
Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study 
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript 
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial 
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial 
Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday - Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027
Your note
Sign in to keep a note on ORKA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGARWAL ARJUN | Officer | Sale | Oct 11, 2026 | 14,219 |
| DAMBKOWSKI CARL | Director | Sale | Jun 11, 2026 | 38,743 |
| EDWARDS LARRY TODD | Officer | Stock Award(Grant) | Aug 23, 2026 | 100,000 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 30, 2026 | 0 |
| GONCALVES JOANA | Officer | Sale | Sep 14, 2026 | 31,771 |
| KLEIN LAWRENCE OTTO | Chief Executive Officer | Sale | Nov 1, 2026 | 923,128 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.68% | 9,057,645 | 901.69M | Jun 29, 2026 |
| Blackrock Inc. | 7.54% | 4,990,181 | 496.77M | Jun 29, 2026 |
| Venrock Adviser, LLC | 6.27% | 4,148,428 | 412.98M | Jun 29, 2026 |
| Fairmount Funds Management LLC | 5.60% | 3,705,262 | 368.86M | Jun 29, 2026 |
| Capital World Investors | 5.14% | 3,401,639 | 338.63M | Jun 29, 2026 |
| RTW Investments LP | 4.74% | 3,139,030 | 312.49M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.60% | 1,724,692 | 171.69M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.44% | 1,614,957 | 160.77M | Sep 29, 2026 |
| SmallCap World Fund Inc | 2.31% | 1,527,592 | 152.07M | Sep 29, 2026 |
| New Economy Fund | 2.00% | 1,323,308 | 131.74M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.97% | 1,304,825 | 129.90M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.95% | 1,294,135 | 128.83M | Aug 30, 2026 |